Next Article in Journal
NPvis: An Interactive Visualizer of Peptidic Natural Product–MS/MS Matches
Next Article in Special Issue
Similar 5F-APINACA Metabolism between CD-1 Mouse and Human Liver Microsomes Involves Different P450 Cytochromes
Previous Article in Journal
Salivary Concentrations of Chemerin, α-Defensin 1, and TNF-α as Potential Biomarkers in the Early Diagnosis of Colorectal Cancer
Previous Article in Special Issue
Human In Vivo Metabolism and Elimination Behavior of Micro-Dosed Selective Androgen Receptor Modulator RAD140 for Doping Control Purposes
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Metabolites
Volume 12
Issue 8
10.3390/metabo12080705
metabolites-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Human Hepatocyte 4-Acetoxy-N,N-Diisopropyltryptamine Metabolite Profiling by Reversed-Phase Liquid Chromatography Coupled with High-Resolution Tandem Mass Spectrometry

by
Sara Malaca
1,
Marilyn A. Huestis
2,
Leonardo Lattanzio
3,
Luigi T. Marsella
3,
Adriano Tagliabracci
1,
Jeremy Carlier
1,* and
Francesco P. Busardò
1
1
Unit of Forensic Toxicology, Section of Legal Medicine, Department of Excellence of Biomedical Sciences and Public Health, Marche Polytechnic University, Via Tronto 10/a, 60126 Ancona, Italy
2
Institute of Emerging Health Professions, Thomas Jefferson University, Philadelphia, PA 19107, USA
3
Forensic Medicine, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy
*
Author to whom correspondence should be addressed.
Metabolites 2022, 12(8), 705; https://doi.org/10.3390/metabo12080705
Submission received: 1 July 2022 / Revised: 19 July 2022 / Accepted: 26 July 2022 / Published: 29 July 2022
(This article belongs to the Special Issue Drugs of Abuse and New Psychoactive Substances – Toxicokinetics Revealed by In Vitro / In Vivo Tools)
Browse Figures
Versions Notes

Abstract

:
Tryptamine intoxications and fatalities are increasing, although these novel psychoactive substances (NPS) are not controlled in most countries. There are few data on the metabolic pathways and enzymes involved in tryptamine biotransformation. 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT) is a synthetic tryptamine related to 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 4-acetyloxy-N,N-dipropyltryptamine (4-AcO-DPT), and 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT). The aim of this study was to determine the best 4-AcO-DiPT metabolites to identify 4-AcO-DiPT consumption through human hepatocyte metabolism and high-resolution mass spectrometry. 4-AcO-DiPT metabolites were predicted in silico with GLORYx freeware to assist in metabolite identification. 4-AcO-DiPT was incubated with 10-donor-pooled human hepatocytes and sample analysis was performed with reversed-phase liquid chromatography coupled with high-resolution tandem mass spectrometry (LC-HRMS/MS) in positive- and negative-ion modes. Software-assisted LC-HRMS/MS raw data mining was performed. A total of 47 phase I and II metabolites were predicted, and six metabolites were identified after 3 h incubation following ester hydrolysis, O-glucuronidation, O-sulfation, N-oxidation, and N-dealkylation. All second-generation metabolites were derived from the only first-generation metabolite detected after ester hydrolysis (4-OH-DiPT). The metabolite with the second-most-intense signal was 4-OH-iPT-sulfate followed by 4-OH-DiPT-glucuronide, indicating that glucuronidation and sulfation are common in this tryptamine’s metabolic pathway. 4-OH-DiPT, 4-OH-iPT, and 4-OH-DiPT-N-oxide are suggested as optimal biomarkers to identify 4-AcO-DiPT consumption.

Graphical Abstract

1. Introduction

Tryptamines are a class of new psychoactive substances (NPS) that share a core structure with the neurotransmitter serotonin, or 5-hydroxytryptamine (5-HT). Tryptamine’s psychedelic effects are produced through agonism of the 5-HT2A and 5-HT2C receptors, with additional contribution from other monoamine transporters [1,2,3,4,5,6,7,8,9,10]. Diverse tryptamine structures have different receptor affinities and resultant effects. 4-AcO-DiPT is a synthetic tryptamine related to 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 4-acetyloxy-N,N-dipropyltryptamine (4-AcO-DPT), and 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT), which currently are not controlled in many countries. 4-AcO-DiPT was identified as early as July 2004, with charges against vendors selling the drug to the public; however, there were no convictions and there was no determination of the legal status of 4-AcO-DiPT [11]. Although the current use of psychedelics is low, tryptamine intake is increasing [1,10] despite limited data on prevalence and patterns of intake. According to psychonauts’ experiences, as reported on the Erowid website, 4-AcO-DiPT is available online and typically administrated orally, with effects similar to those of hallucinogenic mushrooms and 2-(4-bromo-2,5-dimethoxyphenyl)-ethanamine (2C-B) [12]. 4-AcO-DiPT is a white powder available in freebase and HCl salt forms. Both are orally active, with the lower molecular weight freebase being about 10% more potent than the same weight of the HCl salt. 4-AcO-DiPT and 4-OH-DiPT have similar effects if taken orally, though dosage might be different. Oral 4-AcO-DiPT doses start at 3–5 mg; 5–15 mg is considered a “light” dose, while higher doses range between 25 and 40 mg. Users self-report 15–30 mg doses, with onset of effects in 20–60 min, depending on dosage form and stomach contents, and duration of 2–4 h. Its effects, which can appear within 1–4 h, are dose-dependent and include hallucination, dissociation, confusion, and flashbacks, as reported on Erowid by a 4-AcO-DPT user [12]. Over the last decade, there were few intoxication cases and even fewer fatalities due to tryptamines reported in the European Union and North America, although this is likely an underestimation due to missed detections. There are few data on metabolic pathways and specific enzymes involved in tryptamine biotransformation, but it appears that there is not a common metabolic pathway, with the nature and position of substituents changing metabolism. Overall, psychedelic tryptamine use is increasing, raising the importance of laboratory identification of specific metabolites to verify intake and identify potential public health NPS outbreaks. The aim of this study was to determine the optimal 4-AcO-DiPT metabolite biomarkers of consumption for clinical and forensic applications, using in silico metabolite prediction, human hepatocyte metabolism, LC-HRMS/MS analysis, and software-assisted data mining.

2. Results

2.1. In Silico Metabolite Predictions

In silico metabolite predictions are reported in Supplementary Table S1. A total of 47 phase I and II metabolites were predicted, with 10 first-generation metabolites (pM 1–pM 10, by decreasing score) and 37 s-generation metabolites (pM X.1, pM X.4, by decreasing score, and pMX indicating the corresponding first-generation metabolite) (Table 1). First-generation metabolites included hydroxylation, deisopropylation, carboxylation, ester hydrolysis, glucuronidation, and deamination. Second-generation metabolites involved phase I (hydroxylation, dealkylation, carboxylation, and deisopropylation) and phase II (glucuronidation and sulfation) reactions. All predicted metabolites were incorporated in a ddMS2 inclusion list to support LC-HRMS/MS analyses (Supplementary Table S1), and all predicted metabolic transformations were incorporated in the list of potential reactions to support automatic data mining.

2.2. 4-AcO-DiPT Fragmentation Pattern

The 4-AcO-DiPT fragmentation pattern is shown in Figure 1. In positive-ionization mode, ions with m/z 202.0866 resulted from a loss of the diisopropyl amine group followed by loss of the acetyl group producing ions with m/z 160.0758, the fragment with the most intense signal. Further fragmentation yielded ions with m/z 132.0808 then 115.0539 through carbon monoxide and ammonia losses, respectively. Ion m/z 117.0573 was a radical cation typically yielded from hydroxylindole alkylamines [13]. α- and β-cleavage at the nitrogen of the ethylamine chain yielded fragments with m/z 114.1275 and 102.1278, respectively. Fragments with m/z 72.0805 were further produced by isopropyl loss from ions with m/z 114.1275. In addition, the fragments with m/z 259.1815 in negative ionization mode indicate an acetyl loss on the parent drug.

2.3. Metabolite Identification

LC-HRMS data were automatically processed to produce a list of six potential metabolites that were manually checked by the operators. The 4-AcO-DiPT LC-HRMS peak area was 3.00 × 107 in the 3 h incubation with hepatocytes, i.e., 375 times lower than that of the 0 h incubation (1.12 × 1010). Six metabolites were identified after 3 h incubation following ester hydrolysis, O-glucuronidation, O-sulfation, N-oxidation, and N-dealkylation. All second-generation metabolites were derived from the only first-generation metabolite detected, which was produced by ester hydrolysis (4-OH-DiPT, M4). The metabolites are listed from M1 to M6 by ascending retention time (Table 2). The five remaining metabolites all derived from M4 with further phase I and II transformations, including N-deisopropylation (4-OH-iPT, M1 and 4-OH-iPT-sulfate, M2) and N-oxidation at the ethylamine chain (4-OH-DiPT-N-oxide, M6), and O-sulfation (M2 and 4-OH-DiPT-sulfate, M5) and O-glucuronidation (4-OH-DiPT-glucuronidate, M3) in the indole ring. The fragmentation pattern of 4-AcO-DiPT metabolites is shown in Figure 1. The metabolic pathway of the major metabolites is suggested in Figure 2. An extracted-ion chromatogram of 4-AcO-DiPT and metabolites in positive-ionization mode obtained after 3 h incubation with human hepatocytes is presented in Figure 3.

2.3.1. Phase I Metabolites

Ester Hydrolysis

Among the detected metabolites, M4, eluted at 11.82 min, generated the most intense signal with a base peak at m/z 261.1954. 4-OH-DiPT transformation occurred with the loss of the acetyl group and with hydrolysis occurring in the hydroxyl group of the indole ring, as demonstrated by the production of fragments with m/z 160.0753, 114.1274, and 117.0573. The fragments from negative-ionization mode at m/z 132.0243, 114.1275, 132.0804, and 72.0806 showed that the indole core and ethylamine chains were intact. The acetyl loss is indicated by the mass shift of +42.0104 Da from the parent and a difference of -2C -2H -1O on the elemental composition.
M1, M2, M3, M5, and M6 were produced after ester hydrolysis and other metabolic reactions. M3 was detected as a double peak with the same fragmentation pattern.

Ester Hydrolysis and N-Deisopropylation

M1 eluted at 6.31 min, and was formed after N-deisopropylation following ester hydrolysis. A fragment with m/z 160.0752 in the MS/MS spectrum clearly identifies that this reaction occurred in the isopropyl group. 4-OH-iPT revealed a mass shift of +84.0570 Da and a difference of elemental composition of -5C -8H–1O proves this metabolic reaction.

Ester Hydrolysis and N-Oxidation

M6 was detected at 12.53 min and was produced by oxidation on the indole ring after ester hydrolysis. Fragments with m/z 160.0752, 107.0492, and 115.0539 showed that this transformation did not occur in the indole ring, but instead in the diisopropyl amine group of the molecule. This metabolite presented a mass shift of +26.0152 Da and a difference in elemental composition of -2C -2H. The retention time of 4-OH-DiPT-N-oxide was later than that of M4 (4-OH-DiPT), indicating N-oxidation [14,15,16].

2.3.2. Phase II Metabolites

Ester Hydrolysis and O-Glucuronidation

M3, detected at 8.20 min, had the second-most-intense signal. This metabolite was formed after ester hydrolysis and glucuronidation. 4-OH-DiPT-glucuronidate presented a mass shift of −134.0218 Da, differing by +4C +6H +5O from the elemental composition of the parent drug. The presence of fragments with m/z 160.0753 and 114.1274 clearly indicates no transformation in the indole core or the ethylamine chain. Actually, the signal that was detected in negative ionization mode suggests that a glucuronidation reaction occurred.

Ester Hydrolysis and O-Sulfation

M5 eluted at 12.11 min, with fragments having m/z 160.0752 and 115.0539 indicating no reaction at the indole core or the ethylamine chain. 4-OH-DiPT-sulfate showed a mass shift of −37.9466 Da and a difference of -2C -2H +2O +1S on its elemental composition.

Ester Hydrolysis, N-Deisopropylation, and O-Sulfation

M2, eluting at 7.24 min, resulted from ester hydrolysis, N-deisopropylation, and sulfation (produced by M1 O-sulfation). The fragments with m/z 120 prove that no changes were made in the indole core. 4-OH-iPT-sulfate had a mass shift of +4.1002 Da and a difference of -5C -8H +2O +1S in its elemental composition. M2 produced fragments with m/z 219.1487 by sulfate loss, and similar fragments to those of M1.
The fact that a signal was also identified in negative ionization mode suggests that a sulfation reaction occurred to generate both metabolites (M2 and M5).

3. Discussion

In silico metabolite predictions alone are not sufficient to identify the metabolism of specific drugs; however, compilation of HRMS/MS inclusion and exclusion lists and a list of potential metabolic transformations is key to successful Compound Discoverer processing workflow (Supplementary Table S1) and for aiding manual metabolite identification. All six metabolites were predicted. The main phase I and II reactions occurred in the hydroxyl group of the indole ring and in the isopropyl group after ester hydrolysis.
4-AcO-DiPT was incubated with human hepatocytes, which have been proven more suitable for metabolite profiling than human liver microsomes [17]. Hepatocytes are more representative of the physiological liver environment containing both phase I and II drug-metabolizing enzymes, cofactors, and drug transporters [18]. All of these factors allow a better estimation of in vivo metabolism.
The M4 signal was the most intense metabolite signal detected 3 h after incubation with hepatocytes, followed by glucuronidation generating M3. Interestingly, the most intense metabolite (M4) was also detected in the control samples without hepatocytes at 0 and 3 h and at 0 h incubation with hepatocytes but at a much lower intensity than after 3 h incubation, meaning that, although M4 is formed through an enzymatic reaction, it is also spontaneously formed during incubation to a lesser extent. This indicates that M4 formation was overestimated in our experiments. When analyzing authentic samples, digestion (with β-glucuronidase/sulfatase) is preferred to increase the M4 signal. To further understand where the glucuronidation occurred in M3, the 3 h incubations with hepatocytes was reanalyzed after enzymatic hydrolysis with β-glucuronidase, suggesting which part of the molecule was glucuronidated. β-Glucuronidase catalyzes the hydrolysis of O-glucuronides and not N-glucuronides. Comparing the control sample (same hydrolysis conditions but without β-glucuronidase) to the sample with β-glucuronidase, M3 was not present, revealing that the reaction occurred at the hydroxyl group of the molecule and not on the amine group.
An additional consideration is that samples were resuspended in a ratio of 80:20 mobile phase (A:B) to guarantee maximum recovery of the analyte. This can explain the double peak detected for M3. Better peak shapes would be obtained if samples were resuspended with a lower percentage of acetonitrile (mobile phase B). To assure that the double peak was not an isomer, another test was made using a ratio of 95:5 mobile phase (A:B) where no double peak was detected.
Since the parent drug is most likely degraded as the acetyl group is eliminated quickly, toxicologists could report 4-OH-DiPT (M4)-positive cases as from 4-AcO-DiPT intake. The second-most-intense metabolite was M3 (4-OH-DiPT-glucuronide) followed by M1 (4-OH-iPT), indicating that glucuronidation and dealkylation are common in this tryptamine’s metabolic pathway. Others propose that tryptamines do not have a common metabolic pathway and that metabolism changes depending on the nature and position of their substituents, with demethylation, hydroxylation, and dealkylation being the most common phase I reactions, followed by glucuronidation or sulfation [19,20,21,22,23,24]. 4-OH-DiPT, 4-OH-iPT, and 4-OH-DiPT-N-oxide are proposed as biomarkers of 4-AcO-DiPT consumption, but the rapid enzymatic hydrolysis and lower spontaneous hydrolysis of 4-AcO-DiPT to 4-OH-DiPT might create a problem in discerning 4-AcO-DiPT from 4-OH-DiPT consumption. If the parent drug is present even in low concentrations, the ingested drug would be clear, but there is no available information regarding detection of this drug in authentic samples. These results require in vivo confirmation, which is challenging due to the lower prevalence indicated by the small number of 4-AcO-DiPT seizures in recent years.

4. Materials and Methods

4.1. In Silico Metabolites Prediction

4-AcO-DiPT metabolites were predicted with the online GLORYx freeware [25,26]. The metabolite list was generated using the 4-AcO-DiPT with the “phase I and phase II metabolism” option (Table 1, 1st generation). Metabolites with a score higher than 0.40 were selected and reprocessed to simulate a second-step metabolism reaction (Table 1, 2nd generation); the second-generation metabolite score was multiplied by the first-generation metabolite score and scores higher than 0.20 were added to the inclusion list (Supplementary Table S1).

4.2. Chemicals and Reagents

4-AcO-DiPT was obtained from Cayman Chemical (Ann Arbor, MI, USA) and diclofenac was acquired from Sigma Aldrich (Milan, Italy). Stock standards of these chemicals were prepared to 1 mg/mL in LC-MS-grade methanol (Carlo Erba; Cornaredo, Italy). Standards were stored at –20 °C until analysis. Ten-donor-pooled cryopreserved human hepatocytes, thawing medium (TM), and 0.4% trypan blue were purchased from Lonza (Basel, Switzerland). l-Glutamine, HEPES (2-[4-(2-hydroxyethyl)-1-piperazinyl]ethane-sulfonic acid), and Williams’ Medium E were obtained from Sigma Aldrich. l-Glutamine and HEPES were dissolved in Williams’ Medium E to 2 and 20 mmol/L, respectively, prior to analysis. The supplemented Williams’ Medium E (sWME) was stored at 4 °C until incubation. LC-MS-grade acetonitrile, water, and formic acid were obtained from Carlo Erba (Cornaredo, Italy).

4.3. Hepatocytes Incubation

Incubations were conducted as previously described, with small adjustments [27]. Hepatocytes, thawed at 37 °C, were lightly mixed with 50 mL TM in a 50 mL polypropylene conical tube maintained at the same temperature. The tube was centrifuged at 100× g for 5 min and the pellet washed with 50 mL sWME at 37 °C. After centrifugation under the same conditions, cells were resuspended in 2 mL sWME. Hepatocyte viability was evaluated with the trypan blue exclusion test, and sWME volume adjusted to 2 × 106 viable cells/mL. Incubations were prepared in sterile 24-well culture plates with 250 μL hepatocyte suspension and 250 μL 4-AcO-DiPT at 20 μmol/L in sWME at 37 °C. Metabolic reactions were then interrupted with 500 µL ice-cold acetonitrile. Negative controls, i.e., hepatocytes in sWME without 4-AcO-DiPT and 4-AcO-DiPT in sWME without hepatocytes, were incubated for 3 h under the same conditions. Diclofenac was also incubated under the same conditions to ensure proper metabolic activity.

4.4. Sample Preparation

For sample preparation, 100 μL hepatocyte supernate was vortexed with 100 μL acetonitrile, centrifuged at 15,000× g for 10 min at room temperature, and the supernates were dried under nitrogen at 37 °C. Residues were reconstituted with 150 μL mobile phase A (MPA): mobile phase B (MPB) (8:2 v/v), mixed well, and centrifuged for 10 min at 15,000× g at room temperature, and the supernates were transferred into glass inserts in LC autosampler vials. The sample injection volume was 15 μL.

4.5. Instrumental Conditions

LC-HRMS/MS analyses were performed on a DIONEX UltiMate 3000 liquid chromatograph coupled with a Q-Exactive quadrupole-Orbitrap hybrid high-resolution mass spectrometer with a heated-electrospray-ionization (HESI) source (Thermo Scientific, Waltham, MA, USA).

4.6. Liquid Chromatography

Chromatographic separation occurred on a Kinetex® Biphenyl column (150 × 2.1 mm, 2 μm) (Phenomenex, Castel Maggiore, Italy) maintained at 37 ± 1 °C. The 30 min run utilized 0.1% formic acid in water (MPA) and 0.1% formic acid in acetonitrile (MPB) at a 0.4 mL/min flow rate. The gradient was started at 5% MPB for 2 min, increased to 25% MPB by 18 min, further increased to 95% MPB within 2 min, and held for 5 min. The return to initial conditions occurred within 0.1 min, followed by a 4.9 min equilibration, for a total runtime of 30 min. Autosampler temperature was 10 ± 1 °C.

4.7. Mass Spectrometry Conditions

Samples were injected twice, once in positive- and once in negative-ionization mode. HESI source parameters were 50 sheath-gas flow rate, 10 auxiliary-gas flow rate, ±3 kV spray voltage, 300 °C capillary- and auxiliary-gas heater temperature, and 50 S-lens radio frequency; sweep gas was not applied. The orbitrap was calibrated prior to analysis, with a lock mass list for better accuracy. Data were acquired from 1 to 25 min in full-scan HRMS (FullMS)/data-dependent MS/MS (ddMS2) mode. The FullMS acquisition range was m/z 120–700 with a resolution of 70,000 at full width at half maximum (FWHM) at m/z 200. The automatic gain control (AGC) target was 106 and maximum injection time (IT) 200 ms. Up to 5 ddMS2 scans were triggered, with a dynamic exclusion of 2.0 s and an intensity threshold of 104 for each FullMS scan, depending on a priority inclusion list of putative metabolites (Supplementary Table S1) based on in silico predictions and the metabolic fate of 4-AcO-DiPT analogues (Table 1). Other ions not in the inclusion list might also trigger ddMS2 scans. Additionally, background m/z values with high intensity were assessed during injection of blank controls and compiled in an exclusion list in positive- and negative-ion modes. The ddMS2 isolation window was m/z ± 1.2 with a resolution of 17,500 and the normalized collision energy (NCE) was 30, 60, and 90 a.u. The ddMS2 AGC target was 2 × 105 and maximum IT was 64 ms.

4.8. Final Metabolite Identification

LC-HRMS data were processed with Compound Discoverer (v. 3.1.1.12) from Thermo Scientific (Waltham, MA, USA), using a partially automated approach. Briefly, the ions detected in HRMS were compared to a list of theoretical metabolites (intensity threshold, 5 × 103; mass tolerance, 5 ppm). The HRMS/MS spectra and theoretical elemental composition of the ions were compared to online databases (intensity threshold, 105; HRMS mass tolerance, 5 ppm; HRMS/MS mass tolerance, 10 ppm). The chromatographic peaks detected in controls with a similar or higher intensity to that of the peaks detected in the samples were filtered out.

5. Conclusions

This study marks the first characterization of the 4-AcO-DiPT metabolic profile in human hepatocytes using in silico metabolite predictions, LC-HRMS/MS analysis, and software-assisted data mining. We identified six metabolites through ester hydrolysis followed by N-Deisopropylation, O-sulfation, O-glucuronidation, and/or N-Oxidation. We recommend 4-OH-DiPT, 4-OH-iPT, and 4-OH-DiPT-N-oxide as metabolite biomarkers of 4-AcO-DiPT consumption in clinical and forensic toxicology. We propose incorporation of HRMS/MS fragmentation patterns into the online libraries mzCloud and HighResNPS. These findings underscore the value of experimental data and demonstrate how challenging it is to predict NPS metabolism. Our in vitro model offers preliminary findings about 4-AcO-DiPT human metabolism; however, these findings should be verified using samples from authentic positive cases. These data enable analytical toxicologists to identify 4-AcO-DiPT exposure cases.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/metabo12080705/s1, Table S1: Inclusion list for the MS/MS data-dependent acquisition.

Author Contributions

Conceptualization, S.M., M.A.H. and J.C.; methodology, J.C.; formal analysis, S.M. and J.C.; data curation, S.M. and J.C.; writing—original draft preparation, S.M.; writing—review and editing, M.A.H., L.L., L.T.M., A.T., J.C. and F.P.B.; supervision, F.P.B.; project administration, J.C. and F.P.B.; funding acquisition, A.T. and F.P.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Department for Antidrug Policies, in Italy, under the project “Effetti delle NPS: Sviluppo di una multicentrica di ricerca per il potenziamento informativo del Sistema di Allerta Precoce”.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available in the main article and the supplementary materials.

Acknowledgments

The authors would like to thank Simonetta di Carlo, Antonella Bacosi, Michele Sciotti, and Laura Martucci for technical assistance.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Rickli, A.; Moning, O.D.; Hoener, M.C.; Liechti, M.E. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur. Neuropsychopharmacol. 2016, 26, 1327–1337. [Google Scholar] [CrossRef] [Green Version]
  2. Baumeister, D.; Barnes, G.; Giaroli, G.; Tracy, D. Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. Ther. Adv. Psychopharmacol. 2014, 4, 156–169. [Google Scholar] [CrossRef] [Green Version]
  3. Bunzow, J.R.; Sonders, M.S.; Arttamangkul, S.; Harrison, L.M.; Zhang, G.; Quigley, D.I.; Darland, T.; Suchland, K.L.; Pasumamula, S.; Kennedy, J.L.; et al. Amphetamine, 3,4-methylenedioxy methamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol. Pharm. 2001, 60, 1181–1188. [Google Scholar] [CrossRef]
  4. Cozzi, N.V.; Gopalakrishnan, A.; Anderson, L.L.; Feih, J.T.; Shulgin, A.T.; Daley, P.F.; Ruoho, A.E. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. J. Neuraltransm. 2009, 116, 1591–1599. [Google Scholar] [CrossRef]
  5. Fantegrossi, W.E.; Harrington, A.W.; Kiessel, C.L.; Eckler, J.R.; Rabin, R.A.; Winter, J.C.; Coop, A.; Rice, K.C.; Woods, J.H. Hallucinogen-like actions of 5-methoxy-N,N-diisopropyl-tryptamine in mice and rats. Pharmacol. Biochem. Behav. 2006, 83, 122–129. [Google Scholar] [CrossRef]
  6. McKenna, D.J.; Repke, D.B.; Lo, L.; Peroutka, S.J. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology 1990, 29, 193–198. [Google Scholar] [CrossRef]
  7. Luethi, D.; Liechti, M.E. Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. Int. J. Neuropsychopharmacol. 2018, 21, 926–931. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Dos Santos, R.G.; Hallak, J.E.C. Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms. Neurosci. Biobehav. Rev. 2020, 108, 423–434. [Google Scholar] [CrossRef] [PubMed]
  9. Acetoxy-DiPT Legal Status by Erowid. Available online: https://erowid.org/chemicals/4_acetoxy_dipt/4_acetoxy_dipt_law.shtml (accessed on 9 June 2022).
  10. Malaca, S.; Lo Faro, A.F.; Tamborra, A.; Pichini, S.; Busardò, F.P.; Huestis, M.A. Toxicology and Analysis of Psychoactive Tryptamines. Int. J. Mol. Sci. 2020, 21, 9279. [Google Scholar] [CrossRef] [PubMed]
  11. Global Drug Survey (GDS). Available online: https://www.globaldrugsurvey.com/wp-content/themes/globaldrugsurvey/results/GDS2019-Exec-Summary.pdf (accessed on 9 June 2022).
  12. 4-Acetoxy-DiPT Dosage by Erowid. Available online: https://www.erowid.org/chemicals/4_acetoxy_dipt/4_acetoxy_dipt_dose.shtml (accessed on 9 June 2022).
  13. Zhang, Y.; Yuan, B.; Takagi, N.; Wang, H.; Zhou, Y.; Si, N.; Yang, J.; Wei, X.; Zhao, H.; Bian, B. Comparative Analysis of Hydrophilic Ingredients in Toad Skin and Toad Venom Using the UHPLC-HR-MS/MS and UPLC-QqQ-MS/MS Methods Together with the Anti-Inflammatory Evaluation of Indolealkylamines. Molecules 2018, 24, 86. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Swortwood, M.J.; Carlier, J.; Ellefsen, K.N.; Wohlfarth, A.; Diao, X.; Concheiro-Guisan, M.; Kronstrand, R.; Huestis, M.A. In vitro, in vivo and in silico metabolic profiling of α-pyrrolidinopentiothiophenone, a novel thiophene stimulant. Bioanalysis 2016, 8, 65–82. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Diao, X.; Carlier, J.; Zhu, M.; Huestis, M.A. Human Hepatocyte Metabolism of Novel Synthetic Cannabinoids MN-18 and Its 5-Fluoro Analog 5F-MN-18. Clin. Chem. 2017, 63, 1753–1763. [Google Scholar] [CrossRef] [Green Version]
  16. Caspar, A.T.; Gaab, J.B.; Michely, J.A.; Brandt, S.D.; Meyer, M.R.; Maurer, H.H. Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT and their detectability in urine studied by GC-MS, LC-MSn, and LC-HR-MS/MS. Drug Test. Anal. 2018, 10, 184–195. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Carlier, J.; Diao, X.; Huestis, M.A. Synthetic cannabinoid BB-22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography-high resolution mass spectrometry detection. J. Pharm. Biomed. Anal. 2018, 157, 27–35. [Google Scholar] [CrossRef] [PubMed]
  18. Diao, X.; Scheidweiler, K.B.; Wohlfarth, A.; Pang, S.; Kronstrand, R.; Huestis, M.A. In Vitro and In Vivo Human Metabolism of Synthetic Cannabinoids FDU-PB-22 and FUB-PB-22. AAPS J. 2016, 18, 455–464. [Google Scholar] [CrossRef] [Green Version]
  19. Bruni, P.S.; Grafinger, K.E.; Nussbaumer, S.; König, S.; Schürch, S.; Weinmann, W. Study of the in vitro and in vivo metabolism of 4-HO-MET. Forensic Sci. Int. 2018, 290, 103–110. [Google Scholar] [CrossRef]
  20. Grafinger, K.E.; Hädener, M.; König, S.; Weinmann, W. Study of the in vitro and in vivo metabolism of the tryptamine 5-MeO-MiPT using human liver microsomes and real case samples. Drug Test. Anal. 2018, 10, 562–574. [Google Scholar] [CrossRef] [Green Version]
  21. Fabregat-Safont, D.; Barneo-Muñoz, M.; Martinez-Garcia, F.; Sancho, J.V.; Hernández, F.; Ibáñez, M. Proposal of 5-methoxy-N-methyl-N-isopropyltryptamine consumption biomarkers through identification of in vivo metabolites from mice. J. Chromatogr. A 2017, 1508, 95–105. [Google Scholar] [CrossRef]
  22. Manier, S.K.; Felske, C.; Zapp, J.; Eckstein, N.; Meyer, M.R. Studies on the In Vitro and In Vivo Metabolic Fate of the New Psychoactive Substance N-Ethyl-N-Propyltryptamine for Analytical Purposes. J. Anal. Toxicol. 2021, 45, 195–202. [Google Scholar] [CrossRef]
  23. Michely, J.A.; Helfer, A.G.; Brandt, S.D.; Meyer, M.R.; Maurer, H.H. Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS. Anal. Bioanal. Chem. 2015, 407, 7831–7842. [Google Scholar] [CrossRef] [Green Version]
  24. Kamata, T.; Katagi, M.; Kamata, H.T.; Miki, A.; Shima, N.; Zaitsu, K.; Nishikawa, M.; Tanaka, E.; Honda, K.; Tsuchihashi, H. Metabolism of the psychotomimetic tryptamine derivative 5-methoxy-N,N-diisopropyltryptamine in humans: Identification and quantification of its urinary metabolites. Drug Metab. Dispos. 2006, 34, 281–287. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Kops, C.B.; Šícho, M.; Mazzolari, A.; Kirchmair, J. GLORYx: Prediction of the Metabolites Resulting from Phase 1 and Phase 2 Biotransformations of Xenobiotics. Chem. Res. Toxicol. 2021, 34, 286–299. [Google Scholar] [CrossRef] [PubMed]
  26. Stork, C.; Embruch, G.; Šícho, M.; Kops, C.B.; Chen, Y.; Svozil, D.; Kirchmair, J. NERDD: A web portal providing access to in silico tools for drug discovery. Bioinformatics 2020, 36, 1291–1292. [Google Scholar] [CrossRef] [PubMed]
  27. Di Trana, A.; Brunetti, P.; Giorgetti, R.; Marinelli, E.; Zaami, S.; Busardò, F.P.; Carlier, J. In silico prediction, LC-HRMS/MS analysis, and targeted/untargeted data-mining workflow for the profiling of phenylfentanyl in vitro metabolites. Talanta 2021, 235, 122740. [Google Scholar] [CrossRef] [PubMed]
Metabolites 12 00705 g001 550
Figure 1. 4-AcO-DiPT high-resolution tandem-mass-spectrometry spectrum and suggested fragmentation in positive-ionization mode.
Figure 1. 4-AcO-DiPT high-resolution tandem-mass-spectrometry spectrum and suggested fragmentation in positive-ionization mode.
Metabolites 12 00705 g001
Metabolites 12 00705 g002 550
Figure 2. Suggested metabolic fate of 4-AcO-DiPT. Bold indicates major transformations.
Figure 2. Suggested metabolic fate of 4-AcO-DiPT. Bold indicates major transformations.
Metabolites 12 00705 g002
Metabolites 12 00705 g003 550
Figure 3. Extracted-ion chromatogram of 4-AcO-DiPT and metabolites in positive-ionization mode obtained after 3 h incubation with human hepatocytes. Mass tolerance: 5 ppm; m/z values: 219.1489, 261.1955, 277.1907, 299.1057, 303.2059, 341.1525, and 437.2277.
Figure 3. Extracted-ion chromatogram of 4-AcO-DiPT and metabolites in positive-ionization mode obtained after 3 h incubation with human hepatocytes. Mass tolerance: 5 ppm; m/z values: 219.1489, 261.1955, 277.1907, 299.1057, 303.2059, 341.1525, and 437.2277.
Metabolites 12 00705 g003
Table
Table 1. Molecular structure, elemental composition, metabolic transformation, and predictive score of in silico-predicted 4-AcO-DiPT metabolites.
Table 1. Molecular structure, elemental composition, metabolic transformation, and predictive score of in silico-predicted 4-AcO-DiPT metabolites.
Predicted Metabolite (pM)TransformationElemental CompositionScore (%)
pM1N-HydroxylationC18H27N2O363
pM1.1O-GlucuronidationC25H30N2O830
pM1.2N-DeisopropylationC16H21NO322
pM1.3HydroxylationC19H28NO422
pM1.4Hydroxylation (C1″)C18H26N0421
pM2Hydroxylation (C2″)C18H26N2O363
pM2.1O-SulfationC18H24N3O7S60
pM2.2O-GlucuronidationC24H32N2O1039
pM2.3DealkylationC17H24N2O221
pM2.4Hydroxylation (C11)C19H26N2O421
pM2.5Carboxylation (C9)C19H24N2O521
pM3DeisopropylationC15H20N2O263
pM3.1Hydroxylation (C1″)C16H20N2O335
pM3.2DepropylationC13H14O335
pM3.3N-HydroxylationC15H20N2O335
pM3.4N-DeisopropylationC12H14N2O235
pM4Hydroxylation (acetyl)C18H26N2O334
pM4.1O-GlucuronidationC23H32N20928
pM4.2O-SulfationC17H24N206S24
pM5Carboxylation (acetyl)C19H26N2O334
pM5.1O-GlucuronidationC26H36N2O931
pM5.2N-HydroxylationC18H25N2O520
pM5.3DeisopropylationC15H18N20420
pM5.4Hydroxylation (C1″)C18H24N2O520
pM6Ester hydrolysisC19H26N2O34
pM6.1O-SulfationC16H24N2O4S32
pM6.2O-GlucuronidationC22H32N2O729
pM6.3Hydroxylation (C1″)C16H24N2O220
pM6.4N-HydroxylationC16H25N2O220
pM7Hydroxylation (C2)C16H24N2O225
pM8N-GlucuronidationC12H13NO320
pM9Deamination (to aldehyde)C12H13NO320
pM10Deamination (to alcohol)C12H11NO320
Table
Table 2. Metabolic transformation, retention time (RT), accurate mass of molecular ion (hydrogen adduct in positive-ionization mode [M + H]+), elemental composition, deviation from theoretical accurate mass, and liquid chromatography–high-resolution mass spectrometry peak area of 4-AcO-DiPT and metabolites after 3 h incubation with human hepatocytes (HESI positive mode, HESI negative mode).
Table 2. Metabolic transformation, retention time (RT), accurate mass of molecular ion (hydrogen adduct in positive-ionization mode [M + H]+), elemental composition, deviation from theoretical accurate mass, and liquid chromatography–high-resolution mass spectrometry peak area of 4-AcO-DiPT and metabolites after 3 h incubation with human hepatocytes (HESI positive mode, HESI negative mode).
IDTransformationRT (min)[M + H]+Elemental CompositionMass Error (ppm)Peak Areas (HESI+, HESI−)
M1Ester hydrolysis + N-Deisopropylation6.31219.1489C13H18N2O−1.211.10 × 108
M2Ester hydrolysis + N-Deisopropylation
+ O-Sulfation		7.24299.1057C13H18N2O4S−1.233.50 × 107, 5.90 × 107
M3Ester hydrolysis + O-Glucuronidation8.30437.2277C22H32N2O7−1.452.94 × 108, 2.60 × 107
M4Ester hydrolysis11.82261.1955C16H24N2O−2.254.19 × 109
M5Ester hydrolysis + O-Sulfation12.11341.1525C16H24N2O4S−1.424.47 × 107, 2.79 × 107
M6Ester hydrolysis + N-Oxidation12.53277.1907C16H24N2O2−1.357.76 × 106
Parentno transformation15.02303.2059C18H26N2O2−2.673.00 × 107
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Malaca, S.; Huestis, M.A.; Lattanzio, L.; Marsella, L.T.; Tagliabracci, A.; Carlier, J.; Busardò, F.P. Human Hepatocyte 4-Acetoxy-N,N-Diisopropyltryptamine Metabolite Profiling by Reversed-Phase Liquid Chromatography Coupled with High-Resolution Tandem Mass Spectrometry. Metabolites 2022, 12, 705. https://doi.org/10.3390/metabo12080705

AMA Style

Malaca S, Huestis MA, Lattanzio L, Marsella LT, Tagliabracci A, Carlier J, Busardò FP. Human Hepatocyte 4-Acetoxy-N,N-Diisopropyltryptamine Metabolite Profiling by Reversed-Phase Liquid Chromatography Coupled with High-Resolution Tandem Mass Spectrometry. Metabolites. 2022; 12(8):705. https://doi.org/10.3390/metabo12080705

Chicago/Turabian Style

Malaca, Sara, Marilyn A. Huestis, Leonardo Lattanzio, Luigi T. Marsella, Adriano Tagliabracci, Jeremy Carlier, and Francesco P. Busardò. 2022. "Human Hepatocyte 4-Acetoxy-N,N-Diisopropyltryptamine Metabolite Profiling by Reversed-Phase Liquid Chromatography Coupled with High-Resolution Tandem Mass Spectrometry" Metabolites 12, no. 8: 705. https://doi.org/10.3390/metabo12080705

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop